Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Mar 27, 2024 12:07pm
130 Views
Post# 35955703

Buyout

BuyoutIt will be interesting to see if Andrew and whoever else is involved with this Take-Over Bid will stay with this proposal in light of the negative response or will they restructure it and come back with a conventional Buyout ?
Many questions arise if we see an actual buyout proposal:

1. How many shares would have to be bought out ?  How many existing shareholders would be part of the new company and as such would not be bought out ? My guess is that at least 20,000,000 would have to be bought out.
2. What would be the buyout price ?  We all would like to see RPINVESTOR1's and Bluemoon20's price of $2.00+ but realistically that would be for example 20,000,000 x $2.00 = $40,000,000.  Does this group have the capability of raising that kind of money ?  

I will ask the question of all of you:  what is your buyout price ?
<< Previous
Bullboard Posts
Next >>